Pfizer links up with heart disease AI developer Anumana to build cardiac amyloidosis diagnostics
Related Articles
AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance
Healio: An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) clearance from the FDA.October 02, 2023
Way of Diagnosing PH in Common Heart Test Gets FDA Support
Pulmonary Hypertension News: Anumana’s electrocardiogram (ECG)-based algorithm for the early detection of pulmonary hypertension (PH) has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). The…May 26, 2022
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
Developed in collaboration with Mayo Clinic, with support from Pfizer, this ECG-AI algorithm aims to aid physicians in earlier identification of cardiac amyloidosisJune 21, 2023
Inside Mayo Clinic’s AI Factory: How Mayo Clinic is looking to use AI to enhance patient care and clinical decision making
AI Data & Analytics Network: One of the most consequential applications of artificial intelligence (AI) and machine learning (ML) is medicine. Though medical AI is still in its infancy, experts predict that within the…February 28, 2021